Free Trial

Accuray (ARAY) Stock Price, News & Analysis

Accuray logo
$2.14 -0.05 (-2.28%)
As of 01:04 PM Eastern

About Accuray Stock (NASDAQ:ARAY)

Key Stats

Today's Range
$2.12
$2.29
50-Day Range
$1.70
$2.23
52-Week Range
$1.40
$2.99
Volume
389,388 shs
Average Volume
582,369 shs
Market Capitalization
$215.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Buy

Company Overview

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

Accuray Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
92nd Percentile Overall Score

ARAY MarketRank™: 

Accuray scored higher than 92% of companies evaluated by MarketBeat, and ranked 94th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Accuray has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Accuray has received no research coverage in the past 90 days.

  • Read more about Accuray's stock forecast and price target.
  • Earnings Growth

    Earnings for Accuray are expected to grow by 1,200.00% in the coming year, from $0.01 to $0.13 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Accuray is -12.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Accuray is -12.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Accuray has a P/B Ratio of 4.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.57% of the outstanding shares of Accuray have been sold short.
  • Short Interest Ratio / Days to Cover

    Accuray has a short interest ratio ("days to cover") of 5.9.
  • Change versus previous month

    Short interest in Accuray has recently increased by 4.36%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Accuray does not currently pay a dividend.

  • Dividend Growth

    Accuray does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.57% of the outstanding shares of Accuray have been sold short.
  • Short Interest Ratio / Days to Cover

    Accuray has a short interest ratio ("days to cover") of 5.9.
  • Change versus previous month

    Short interest in Accuray has recently increased by 4.36%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Accuray has a news sentiment score of 1.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Accuray this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for ARAY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Accuray to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Accuray insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.23% of the stock of Accuray is held by insiders.

  • Percentage Held by Institutions

    64.08% of the stock of Accuray is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Accuray's insider trading history.
Receive ARAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accuray and its competitors with MarketBeat's FREE daily newsletter.

ARAY Stock News Headlines

Despite the Tesla Crash, These Traders Are 9 for 9
Most Tesla shareholders are disappointed in the stock's performance in 2024, with a 30% decline year to date. But not this guy… One trader has found a way to turn Tesla’s downfall into a flurry of opportunity. In fact, he hasn’t lost a single trade on Tesla this year! See for yourself (Notice how short of a time period he holds onto the stock):
Accuray Incorporated: Cheap, But With Caveats
Accuray Stockholders Approve Plans and Appoint New Officer
See More Headlines

ARAY Stock Analysis - Frequently Asked Questions

Accuray's stock was trading at $1.98 at the beginning of 2025. Since then, ARAY shares have increased by 11.1% and is now trading at $2.20.
View the best growth stocks for 2025 here
.

Accuray Incorporated (NASDAQ:ARAY) announced its earnings results on Wednesday, November, 6th. The medical equipment provider reported ($0.04) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.04). The medical equipment provider had revenue of $101.55 million for the quarter, compared to the consensus estimate of $98.10 million. Accuray had a negative trailing twelve-month return on equity of 36.93% and a negative net margin of 3.72%.

Accuray subsidiaries include these companies: Morphormics Inc., TomoTherapy Incorporated, Accuray Accelerator Technology (Chengdu) Company Limited, Accuray Asia Ltd., Accuray Belgium BVBA, Accuray Brasil Comércio, Accuray Cayman Islands, and others.

Shares of ARAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Accuray investors own include Waste Connections (WCN), American Water Works (AWK), Voyager Therapeutics (vygr), AUO (AUOTY), The RMR Group (RMR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
11/06/2024
Today
1/07/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:ARAY
CUSIP
00439710
Employees
987
Year Founded
1990

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$9.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+320.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-15,550,000.00
Pretax Margin
-3.18%

Debt

Sales & Book Value

Annual Sales
$444.20 million
Book Value
$0.45 per share

Miscellaneous

Free Float
96,311,000
Market Cap
$215.21 million
Optionable
Optionable
Beta
1.47

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

This page (NASDAQ:ARAY) was last updated on 1/7/2025 by MarketBeat.com Staff
From Our Partners